Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 45: 1960-1966, 1999;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (80)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Magklara, A.
Right arrow Articles by Diamandis, E. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Magklara, A.
Right arrow Articles by Diamandis, E. P.
Related Collections
Right arrow Evidence Based Laboratory Medicine and Test Utilization
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 1999;45:1960-1966.)
© 1999 American Association for Clinical Chemistry, Inc.

Articles

The Combination of Human Glandular Kallikrein and Free Prostate-specific Antigen (PSA) Enhances Discrimination Between Prostate Cancer and Benign Prostatic Hyperplasia in Patients with Moderately Increased Total PSA

Angeliki Magklara1, Andreas Scorilas1, William J. Catalona2 and Eleftherios P. Diamandis1,a

1 Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada M5G 1X5, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.

2 Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110.
a Address correspondence to this author at: Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Ave., Toronto, Ontario, Canada M5G 1X5. Fax 416-586-8628; e-mail ediamandis{at}mtsinai.on.ca

Background: Prostate-specific antigen (PSA) is the most reliable tumor marker available and is widely used for the diagnosis and management of prostate cancer. Unfortunately, PSA cannot distinguish efficiently between benign and malignant disease of the prostate, especially within the range of 4–10 µg/L. Among the refinements developed to enhance PSA specificity is the free/total PSA ratio, which is useful in discriminating between the two diseases within the diagnostic "gray zone". Recent data indicate that human glandular kallikrein (hK2), a protein with high homology to PSA, may be an additional serum marker for the diagnosis and monitoring of prostate cancer.

Methods: We analyzed 206 serum samples (all before treatment was initiated) from men with histologically confirmed benign prostatic hyperplasia (n = 100) or prostatic carcinoma (n = 106) with total PSA in the range of 2.5–10 µg/L. Total and free PSA and hK2 were measured with noncompetitive immunological procedures. Statistical analysis was performed to investigate the potential utility of the various markers or their combinations in discriminating between benign prostatic hyperplasia and prostatic carcinoma.

Results: hK2 concentrations were not statistically different between the two groups of patients. There was a strong positive correlation between hK2 and free PSA in the whole patient population. hK2/free PSA ratio (area under the curve = 0.69) was stronger predictor of prostate cancer than the free/total PSA ratio (area under the curve = 0.64). At 95% specificity, the hK2/free PSA ratio identified 30% of patients with total PSA between 2.5–10 µg/L who had cancer. At 95% specificity, the hK2/free PSA ratio identified 25% of patients with total PSA between 2.5 and 4.5 µg/L who had cancer.

Conclusions: Our data suggest that hK2 in combination with free and total PSA can enhance the biochemical detection of prostate cancer in patients with moderately increased total PSA concentrations. More specifically, the hK2/free PSA ratio appears to be valuable in identifying a subset of patients with total PSA between 2.5 and 4.5 µg/L who have high probability of cancer and who should be considered for biopsy.




The following articles in journals at HighWire Press have cited this article:


Home page
 Anticancer ResHome page
B. BICKERS and C. AUKIM-HASTIE
New Molecular Biomarkers for the Prognosis and Management of Prostate Cancer - The Post PSA Era
Anticancer Res, August 1, 2009; 29(8): 3289 - 3298.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
D. Korbakis, A. K. Gregorakis, and A. Scorilas
Quantitative Analysis of Human Kallikrein 5 (KLK5) Expression in Prostate Needle Biopsies: An Independent Cancer Biomarker
Clin. Chem., May 1, 2009; 55(5): 904 - 913.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
N. Emami and E. P. Diamandis
Utility of Kallikrein-Related Peptidases (KLKs) as Cancer Biomarkers
Clin. Chem., October 1, 2008; 54(10): 1600 - 1607.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. K. Nam, W. W. Zhang, L. H. Klotz, J. Trachtenberg, M. A.S. Jewett, J. Sweet, A. Toi, S. Teahan, V. Venkateswaran, L. Sugar, et al.
Variants of the hK2 Protein Gene (KLK2) Are Associated with Serum hK2 Levels and Predict the Presence of Prostate Cancer at Biopsy.
Clin. Cancer Res., November 1, 2006; 12(21): 6452 - 6458.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
L. Holzscheiter, J. C. Biermann, M. Kotzsch, P. Prezas, J. Farthmann, G. Baretton, T. Luther, V. C.G. Tjan-Heijnen, M. Talieri, M. Schmitt, et al.
Quantitative Reverse Transcription-PCR Assay for Detection of mRNA Encoding Full-Length Human Tissue Kallikrein 7: Prognostic Relevance of KLK7 mRNA Expression in Breast Cancer
Clin. Chem., June 1, 2006; 52(6): 1070 - 1079.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Nagahara, K. Mimori, T. Utsunomiya, G. F. Barnard, M. Ohira, K. Hirakawa, and M. Mori
Clinicopathologic and Biological Significance of Kallikrein 6 Overexpression in Human Gastric Cancer
Clin. Cancer Res., October 1, 2005; 11(19): 6800 - 6806.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Dong, H. Zhang, A. C. Gao, J. R. Marshall, and C. Ip
Androgen receptor signaling intensity is a key factor in determining the sensitivity of prostate cancer cells to selenium inhibition of growth and cancer-specific biomarkers
Mol. Cancer Ther., July 1, 2005; 4(7): 1047 - 1055.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Ogawa, T. Utsunomiya, K. Mimori, F. Tanaka, H. Inoue, H. Nagahara, S. Murayama, and M. Mori
Clinical Significance of Human Kallikrein Gene 6 Messenger RNA Expression in Colorectal Cancer
Clin. Cancer Res., April 15, 2005; 11(8): 2889 - 2893.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
C. A. Borgono, I. P. Michael, and E. P. Diamandis
Human Tissue Kallikreins: Physiologic Roles and Applications in Cancer
Mol. Cancer Res., May 1, 2004; 2(5): 257 - 280.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Shigemasa, L. Gu, H. Tanimoto, T. J. O'Brien, and K. Ohama
Human Kallikrein Gene 11 (KLK11) mRNA Overexpression Is Associated with Poor Prognosis in Patients with Epithelial Ovarian Cancer
Clin. Cancer Res., April 15, 2004; 10(8): 2766 - 2770.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. A. Borgono, L. Grass, A. Soosaipillai, G. M. Yousef, C. D. Petraki, D. H. C. Howarth, S. Fracchioli, D. Katsaros, and E. P. Diamandis
Human Kallikrein 14: A New Potential Biomarker for Ovarian and Breast Cancer
Cancer Res., December 15, 2003; 63(24): 9032 - 9041.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Nakamura, A. Scorilas, C. Stephan, K. Jung, A. R. Soosaipillai, and E. P. Diamandis
The Usefulness of Serum Human Kallikrein 11 for Discriminating between Prostate Cancer and Benign Prostatic Hyperplasia
Cancer Res., October 1, 2003; 63(19): 6543 - 6546.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
P. M. Bossuyt, J. B. Reitsma, D. E. Bruns, C. A. Gatsonis, P. P. Glasziou, L. M. Irwig, D. Moher, D. Rennie, H. C.W. de Vet, and J. G. Lijmer
The STARD Statement for Reporting Studies of Diagnostic Accuracy: Explanation and Elaboration
Ann Intern Med, January 7, 2003; 138(1): W1 - W12.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
P. M. Bossuyt, J. B. Reitsma, D. E. Bruns, C. A. Gatsonis, P. P. Glasziou, L. M. Irwig, D. Moher, D. Rennie, H. C.W. de Vet, and J. G. Lijmer
The STARD Statement for Reporting Studies of Diagnostic Accuracy: Explanation and Elaboration
Clin. Chem., January 1, 2003; 49(1): 7 - 18.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
G. M. Yousef, A. Scorilas, L. G. Kyriakopoulou, L. Rendl, M. Diamandis, R. Ponzone, N. Biglia, M. Giai, R. Roagna, P. Sismondi, et al.
Human Kallikrein Gene 5 (KLK5) Expression by Quantitative PCR: An Independent Indicator of Poor Prognosis in Breast Cancer
Clin. Chem., August 1, 2002; 48(8): 1241 - 1250.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. M. Yousef, L. G. Kyriakopoulou, A. Scorilas, S. Fracchioli, B. Ghiringhello, M. Zarghooni, A. Chang, M. Diamandis, G. Giardina, W. J. Hartwick, et al.
Quantitative Expression of the Human Kallikrein Gene 9 (KLK9) in Ovarian Cancer: A New Independent and Favorable Prognostic Marker
Cancer Res., November 1, 2001; 61(21): 7811 - 7818.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L.-Y. Luo, D. Katsaros, A. Scorilas, S. Fracchioli, R. Piccinno, I. A. Rigault de la Longrais, D. J. C. Howarth, and E. P. Diamandis
Prognostic Value of Human Kallikrein 10 Expression in Epithelial Ovarian Carcinoma
Clin. Cancer Res., August 1, 2001; 7(8): 2372 - 2379.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. A. Finlay, J. R. Day, C. L. Evans, R. Carlson, K. Kuus-Reichel, L. S. Millar, S. D. Mikolajczyk, M. Goodmanson, G. G. Klee, and H. G. Rittenhouse
Development of a Dual Monoclonal Antibody Immunoassay for Total Human Kallikrein 2
Clin. Chem., July 1, 2001; 47(7): 1218 - 1224.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
G. M. Yousef and E. P. Diamandis
The New Human Tissue Kallikrein Gene Family: Structure, Function, and Association to Disease
Endocr. Rev., April 1, 2001; 22(2): 184 - 204.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
A. Magklara, A. Scorilas, D. Katsaros, M. Massobrio, G. M. Yousef, S. Fracchioli, S. Danese, and E. P. Diamandis
The Human KLK8 (Neuropsin/Ovasin) Gene: Identification of Two Novel Splice Variants and Its Prognostic Value in Ovarian Cancer
Clin. Cancer Res., April 1, 2001; 7(4): 806 - 811.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
K. M. Slawin, S. F. Shariat, C. Nguyen, A. K. Leventis, W. Song, M. W. Kattan, C. Y. F. Young, D. J. Tindall, and T. M. Wheeler
Detection of Metastatic Prostate Cancer Using a Splice Variant-specific Reverse Transcriptase-Polymerase Chain Reaction Assay for Human Glandular Kallikrein
Cancer Res., December 1, 2000; 60(24): 7142 - 7148.
[Abstract] [Full Text]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
C. Stephan, K. Jung, M. Lein, P. Sinha, D. Schnorr, and S. A. Loening
Molecular Forms of Prostate-specific Antigen and Human Kallikrein 2 as Promising Tools for Early Diagnosis of Prostate Cancer
Cancer Epidemiol. Biomarkers Prev., November 1, 2000; 9(11): 1133 - 1147.
[Abstract] [Full Text]

Home page
 JCOHome page
R. K. Nam, E. P. Diamandis, A. Toi, J. Trachtenberg, A. Magklara, A. Scorilas, P. A. Papnastasiou, M. A. S. Jewett, and S. A. Narod
Serum Human Glandular Kallikrein-2 Protease Levels Predict the Presence of Prostate Cancer Among Men With Elevated Prostate-Specific Antigen
J. Clin. Oncol., March 1, 2000; 18(5): 1036 - 1036.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American Association for Clinical Chemistry.